Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/03/2005US20050048639 Caspase-8 binding protein, its preparation and use
03/03/2005US20050048584 Method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases associated peptides and use thereof
03/03/2005US20050048537 Novel human lipocalin homologs and polynucleotides encoding the same
03/03/2005US20050048528 Using immunoglobulins and diagnostic and/or prognostic tool for detection and treatment of cell proliferative disorders; immunodiagnostics; immunotherapy
03/03/2005US20050048520 Nogo receptor homologs
03/03/2005US20050048511 Truncated glycogen synthase kinase 3 protein for use in identifying modulators to treat diabetes, inflammation and nervous system disorders; drug screening
03/03/2005US20050048488 Expression vector comprising nucleotide sequences coding excitatory amino acid transporter 2 (EAAT2) proteins for use in identifying modulator for treatment and preention of neurological or psychiatric disorder
03/03/2005US20050048479 Adenylyl and guanylyl cyclases
03/03/2005US20050048137 Extract of plant dendrobii caulis and preparing process thereof
03/03/2005US20050048132 Use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
03/03/2005US20050048118 Core containing lipophilic matric with drug; protective coatings
03/03/2005US20050048107 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml
03/03/2005US20050048106 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml
03/03/2005US20050048104 Transdermal drug delivery devices comprising a polyurethane drug reservoir
03/03/2005US20050048078 Protein polymer having unfold activity on higher-order structure of protein
03/03/2005US20050048049 A humanized antibody that binds to soluble A beta; may be monoclonal, polyclonal, single chain or fused to a heterologous polypeptide
03/03/2005US20050048039 Administering exogenous monocyte cells loaded with corrective agent; chemotactic factor for macrophages; diagnosis of bone disorders, anticarcinogenic agents, rheumatic disorders; Alzheimer's disease; Parkinson's disease; Huntington's disease; multiple sclerosis; stroke
03/03/2005US20050048035 Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
03/03/2005US20050048034 Using adipose stem cells to treat ischemic ulcer, diabetic and traumatic wounds; regenerative medicine
03/03/2005US20050047958 Methods for sterilizing preparations of digestive enzymes
03/03/2005DE10334187A1 Substituierte 2-Aminotetraline zur Behandlung von Depressionen Substituted 2-aminotetralines for the treatment of depression
03/03/2005CA2536435A1 Drug containing chymase inhibitor as the active ingredient
03/03/2005CA2536313A1 Fused pyrimidine derivative and use thereof
03/03/2005CA2536280A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005CA2536275A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
03/03/2005CA2536053A1 Powder formulation comprising the cgrp antagonist 1-(n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine
03/03/2005CA2535811A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005CA2535337A1 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
03/03/2005CA2535063A1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
03/03/2005CA2532020A1 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
03/03/2005CA2529401A1 Processes for preparing 3-benzazepines
03/02/2005EP1510519A1 Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives
03/02/2005EP1510518A2 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels
03/02/2005EP1510516A1 Pyrazole compound and medicinal composition containing the same
03/02/2005EP1510218A1 Extract of plant dendrobii caulis and preparing process thereof
03/02/2005EP1509772A2 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2)
03/02/2005EP1509621A1 Treatment with cytokines for alzheimer's disease
03/02/2005EP1509618A2 Autoimmune conditions and nadph oxidase defects
03/02/2005EP1509532A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509530A1 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509526A2 Imidazo(1,2-a)pyrazin-8-ylamines, method of making, and method of use thereof
03/02/2005EP1509522A1 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
03/02/2005EP1509506A1 Pyridazine derivatives
03/02/2005EP1509504A1 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
03/02/2005EP1509501A1 1-(aminoalkyl)-3-sulfonylindole and -indazole derivatives as 5-hydroxytryptamine-6 ligands
03/02/2005EP1509499A1 Pyrrole compounds for the treatment of prostaglandin mediated diseases
03/02/2005EP1509498A1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
03/02/2005EP1509495A1 Anilino liver x-receptor modulators
03/02/2005EP1509489A1 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
03/02/2005EP1509251A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
03/02/2005EP1509249A2 Inclusion complexes of rosiglitazone
03/02/2005EP1509247A1 Use of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating dieseases
03/02/2005EP1509241A1 Novel uses of cephaibols
03/02/2005EP1509233A1 Liquid formulation of decitabine and use of the same
03/02/2005EP1509232A1 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
03/02/2005EP1509227A1 A buffered, liquid nicotine composition for pulmonary administration
03/02/2005EP1509222A1 Adduct of topiramate and tramadol hydrochloride and uses thereof
03/02/2005EP1509217A1 Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (cox 2) inhibitor(s)
03/02/2005EP1509216A1 Active ingredient salts and esters of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol
03/02/2005EP1509213A2 Acetamides and benzamides that are useful in treating sexual dysfunction
03/02/2005EP1509207A1 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
03/02/2005EP1509188A2 Compounds active at the glucocorticoid receptor ii
03/02/2005EP1509182A1 Implantable polymeric device for sustained release of buprenorphine
03/02/2005EP1416966A4 Methods for treating joint inflammation, pain, and loss of mobility
03/02/2005EP1296650B1 Methods and compositions for treating pain of the mucous membrane
03/02/2005EP1278741B1 Muscarinic agonists
03/02/2005EP1244649B1 Cyclic amp-specific phosphodiesterase inhibitors
03/02/2005EP1141294B1 Method of enhancing the biological activity of ligands
03/02/2005EP1135105B1 Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
03/02/2005EP1123100B1 Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof
03/02/2005EP1086082B9 Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
03/02/2005EP1030667B1 Use of mirtazapine for the manufacture of a medicament for treating sleep apneas
03/02/2005EP1014976B1 Novel substituted imidazole compounds
03/02/2005EP0948499B1 Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them
03/02/2005EP0824530B1 Aryl glycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
03/02/2005CN1589271A Fused heterocyclic succinimide compounds and analogs thereof as modulators of nuclear hormone receptor function
03/02/2005CN1589269A Heteroindanes: a new class of potent cannabimimetic ligands
03/02/2005CN1589268A Substituted benzopyrans compounds as selective estrogen receptor-beta agonists
03/02/2005CN1589261A Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
03/02/2005CN1589260A Heterocyclic compounds and methods of use thereof
03/02/2005CN1589258A Novel beta -phenyl- alpha -oxysubstituted propionic derivatives: process for their preparation and their use in the preparation of pharmaceutically important compounds
03/02/2005CN1589256A Polycrystalline forms of sertraline hydrochloride and compeosition containing them, and method for preparing sertraline hydrochloride polycrystalline forms and amorphous matter
03/02/2005CN1589152A Novel human beta 2 integrin alpha subunit
03/02/2005CN1589151A Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
03/02/2005CN1589148A Succinic acid salts of 5, 8, 14-triazatetracyclo'10.3.1.0 less than2, 11greater than.0 less than 4, 9 greater than-hexadeca-2(11), 3, 5, 7, 9-pentaene and pharmaceutical compositions thereof
03/02/2005CN1589147A Use of N-(indolecarbonyl-)piperazine derivatives
03/02/2005CN1589146A Benzothiazole derivatives as adenosine receptor ligands
03/02/2005CN1589137A Treatment of neurodegenerative and cardiovascular disorders
03/02/2005CN1589134A Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
03/02/2005CN1589103A Nestin-expressing hair follicle stem cells
03/02/2005CN1586610A Process for preparing granular powder for treating neurosism and quality control method
03/02/2005CN1586597A Ginseng oral disintegration tablet and its preparing process
03/02/2005CN1586596A American ginseng and its extract oral disintegration tablet and its preparing process
03/02/2005CN1586591A Chinese medicnie preparation for treating senile dementia
03/02/2005CN1586581A Lozenge for sobering and clearing smoke
03/02/2005CN1586556A Oral liquid for detoxifying and drug giving up
03/02/2005CN1586540A Zhenge lozenge having sobering, liver protection and stomach protection health function
03/02/2005CN1586533A Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis
03/02/2005CN1586525A Chinese medicinal preparation for paraplegia good for walking
03/02/2005CN1586494A Helicidum oral disintegation tablet and its preparing method
1 ... 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 ... 1833